109 related articles for article (PubMed ID: 15883700)
1. Autoimmune muscular pathologies.
Dalakas MC
Neurol Sci; 2005 May; 26 Suppl 1():S7-8. PubMed ID: 15883700
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory myopathies: evaluation and management.
Greenberg SA
Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic targets for idiopathic inflammatory myopathies.
De Bleecker JL; Creus KK; De Paepe B
Drug News Perspect; 2006 Nov; 19(9):549-57. PubMed ID: 17220960
[TBL] [Abstract][Full Text] [Related]
4. [Therapy with immunoglobulins in neurologic autoimmune diseases. Indications and mechanism of action].
Gold R; Hartung HP; Toyka KV
Fortschr Neurol Psychiatr; 1995 Jan; 63(1):17-29. PubMed ID: 7883268
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin therapy for neuromuscular disorders.
Ross MA
Semin Neurol; 2007 Sep; 27(4):340-6. PubMed ID: 17701871
[TBL] [Abstract][Full Text] [Related]
6. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
7. Update on idiopathic inflammatory myopathies.
Briani C; Doria A; Sarzi-Puttini P; Dalakas MC
Autoimmunity; 2006 May; 39(3):161-70. PubMed ID: 16769649
[TBL] [Abstract][Full Text] [Related]
8. Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action.
Lytton SD; Denton CP; Nutzenberger AM
Ann N Y Acad Sci; 2007 Sep; 1110():285-96. PubMed ID: 17911443
[TBL] [Abstract][Full Text] [Related]
9. [Poxviral immunomodulatory proteins as new therapeutics for immunocorrection].
Nepomniashchikh TS; Shchelkunov SN
Mol Biol (Mosk); 2008; 42(5):904-12. PubMed ID: 18988538
[TBL] [Abstract][Full Text] [Related]
10. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
[TBL] [Abstract][Full Text] [Related]
11. beta-Glycosphingolipids as immune modulators.
Adar T; Ilan Y
J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
[TBL] [Abstract][Full Text] [Related]
12. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis.
Dimitri D; Benveniste O; Dubourg O; Maisonobe T; Eymard B; Amoura Z; Jean L; Tiev K; Piette JC; Klatzmann D; Herson S; Boyer O
Brain; 2006 Apr; 129(Pt 4):986-95. PubMed ID: 16455793
[TBL] [Abstract][Full Text] [Related]
13. Restoring function in exhausted CD8 T cells during chronic viral infection.
Barber DL; Wherry EJ; Masopust D; Zhu B; Allison JP; Sharpe AH; Freeman GJ; Ahmed R
Nature; 2006 Feb; 439(7077):682-7. PubMed ID: 16382236
[TBL] [Abstract][Full Text] [Related]
14. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
Szegedi G
Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
Pongratz D
J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
[TBL] [Abstract][Full Text] [Related]
16. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
17. Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells.
Chen Y; Li J; Zhang J; Zhao T; Zou L; Tang Y; Zhang X; Wu Y
Int Immunopharmacol; 2005 Aug; 5(9):1446-57. PubMed ID: 15953571
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory, immune, and viral aspects of inclusion-body myositis.
Dalakas MC
Neurology; 2006 Jan; 66(2 Suppl 1):S33-8. PubMed ID: 16432143
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin therapy for autoimmune diseases.
Arnson Y; Shoenfeld Y; Amital H
Autoimmunity; 2009 Sep; 42(6):553-60. PubMed ID: 19657774
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.
Ding H; Wu X; Gao W
Clin Immunol; 2005 May; 115(2):184-91. PubMed ID: 15885642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
